Evidence map›Paper›PMID 31316989›Full record

ArticleFrontiers in medicine2019

1D and 2D-HSQC NMR: Two Methods to Distinguish and Characterize Heparin From Different Animal and Tissue Sources.

Lucio Mauri, Maria Marinozzi, Nisarga Phatak, Michael Karfunkle, Kalib St Ange, Marco Guerrini, David A Keire, Robert J Linhardt

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. The Content and Location of 3-Biomolecules · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Heparinase Digestion of 3-Frontiers in medicine · 2022
    Article
  10. Article
  11. Review
  12. General Considerations for Diversifying Heparin Drug Products by Improving the Current Heparin Manufacturing Process and Reintroducing Bovine Sourced Heparin to the US Market.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Lucio MauriNMR Center, Istituto di Ricerche Chimiche e Biochimiche "G. Ronzoni," Milan, Italy.
Maria MarinozziNMR Center, Istituto di Ricerche Chimiche e Biochimiche "G. Ronzoni," Milan, Italy.
Nisarga PhatakDivision of Pharmaceutical Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, St. Louis, MO, United States.
Michael KarfunkleDivision of Pharmaceutical Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, St. Louis, MO, United States.
Kalib St AngeDepartment of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.
Marco GuerriniNMR Center, Istituto di Ricerche Chimiche e Biochimiche "G. Ronzoni," Milan, Italy.
David A KeireDivision of Pharmaceutical Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, St. Louis, MO, United States.
Robert J LinhardtDepartment of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.
Istituto di Ricerche Chimiche e Biochimiche G. Ronzoni · ITRensselaer Polytechnic Institute · USUnited States Food and Drug Administration · USCenter for Drug Evaluation and Research · US

Funding

In vitro synthesis of recombinant heparan sulfateR01HL094463 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN, PAWLINSKI, RAFAL L · 2009 to 2021
$5.2M
Endothelial glycocalyx reconstitution during sepsisR01HL125371 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI LINHARDT, ROBERT J, SCHMIDT, ERIC PETER · 2014 to 2018
$3.4M
The role ofglycosaminoglycan N-sulfation in glomerular biology/pathobiologyR01DK111958 · NIDDK · LOUISIANA STATE UNIV HSC SHREVEPORT · PI MCCARTHY, KEVIN JOHN · 2017 to 2021
$2.6M
An Automated Platform for the CE-MS Analysis of GlycosaminoglycansU01CA231074 · NCI · UNIVERSITY OF GEORGIA · PI AMSTER, I JONATHAN · 2018 to 2020
$895k
NCI NIH HHS U01 CA231074NHLBI NIH HHS R01 HL094463NHLBI NIH HHS R01 HL125371NIDDK NIH HHS R01 DK111958
6 · The paper itself

Abstract

The US Food and Drug Administration has encouraged the reintroduction of bovine heparin drug product to the US market to mitigate the risks of heparin shortages and potential adulteration or contamination of the primary source which is porcine heparin. Here, a 1D-NMR method was applied to compare heparin sodium of bovine intestinal origin with that of bovine lung, porcine, or ovine intestinal origin. The results showed that a simple 1D test using NMR signal intensity ratios among diagnostic signals of the proton spectra uniquely identified the origin of heparin and concomitantly could be used to assure the correct sample labeling. However, a limitation of the use of only mono-dimensional spectra is that these spectra may not provide sufficiently detailed information on the composition of heparin batches to adequately determine the quality of this complex product. As an alternative, a higher resolution quantitative 2D-HSQC method was used to calculate the percentage of mono- and disaccharides, distinguish the origin of heparin and, simultaneously, assess the heparin composition. The 2D-HSQC method is proposed to provide sufficient information to evaluate the quality of industrial production process used to make the drug substance. Together, the 1D and 2D data produced by these measurements can be used to assure the identity and purity of this widely used drug.

Indexed as

animal originheparinHSQCNMRpharmacopeia

Identifiers

PMID31316989
PMCPMC6610300
OpenAlexW2956148198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.